Cai Lian News Agency, November 17 (Reporter Zhou Xiaoya) As the sector market rotation continues, the research of fund companies is also more intensive. Wind data shows that as of November 17, fund companies have participated in a total of 340 listed companies this month, of which nearly half have conducted more than 70 surveys.
In the frequent research, there are many well-known fund managers. For example, Liu Changchang, a fund manager under Huaan Fund, appeared at an online meeting held by Longgao on November 15. The latest investor relations activity record sheet also shows that a number of public funds, including well-known fund managers such as Zhao Bei of ICBC Credit Suisse Fund and Wang Pei of China Europe Fund, participated in its research.
Overall, Yiheda is a listed institution that has been investigated by multiple fund companies this month, and more than 60 fund companies from 3 listed companies such as Huacan Optoelectronics, BOE A, and Hengdian Dongci participated in the survey. From the perspective of industry sectors, the research of individual stocks in electronic devices, semiconductors, healthcare equipment and other sectors has been favored by many fund companies. Among the many surveys, are there any new trends in fund managers' attention to individual stocks or sectors?
Liu Changchang appeared in Longgao shares research
On November 16, Longgao disclosed an investor relations activity record sheet showing that Liu Changchang, a fund manager under Huaan Fund, participated in the company's online meeting held on November 15. The meeting mainly focused on the company's production capacity and kaolin products, the company's downstream market pattern, and future development strategy planning.
Longgao said that the company integrates mining, mineral processing, research and development, and sales, and is a national production and supply base for kaolin for ceramic raw materials. As the source enterprise of the industrial chain, the company's downstream is mainly porcelain clay production enterprises and ceramic enterprises. Longyan Donggongxia Mine under the company is a large high-quality kaolin mine in mainland China, which has formed a high-quality stable supply of large-scale.
Looking forward to the future, they will be rooted in the non-metallic mineral resources industry, expand and open up the industrial chain appropriately, broaden the sources of income, and develop into a leading enterprise in the global non-metallic mineral industry chain such as mining, processing and application. On the one hand, it will further increase the reserves of non-metallic mineral resources including but not limited to kaolin, limestone, fluorite ore, etc.; On the other hand, it will extend the non-metallic mineral industry chain to the deep processing industry related to the application field, acquire high-quality enterprises upstream and downstream of the non-metallic mineral industry chain, and focus on high-end ceramic processing, deep processing of quartz stone (silicon) materials (photovoltaic/sheet direction), deep processing of bentonite materials, fluorine chemical manufacturing and other new material diversified businesses.
As of the end of June this year, 12 fund companies were institutional investors in the stock, and Cai Songsong's Sino Analytica Growth, Sino Analytica and Xin also held the stock. However, on the whole, the number of holdings in the products of each fund house is small, so the change in the position of the stock is not disclosed in the third quarterly report.
Since the fourth quarter, Longgao's share price has been rising, and as of November 16, the stock price has risen by more than 20% in the fourth quarter. Behind the rise in stock prices, Longgao achieved operating income of 85.0466 million yuan in the third quarter of 2022, a year-on-year increase of 22.22%; The net profit attributable to shareholders of the listed company was 33.821 million yuan, a year-on-year increase of 42.39%.
For the stock, the research report of Northeast Securities mentioned that as a leading kaolin supplier, the company's resource advantages are expected to gradually be realized, giving an "overweight" rating in mid-September this year, and the company's revenue in 2023 will be 407 million yuan, the net profit attributable to the parent will be 139 million yuan, and the PE will be 17.43x.
The company's position in the industrial chain is one of the reasons why Liu Changchang pays attention to Longgao shares. In the third quarterly report of Huaan Culture and Sports Health in 2022, Liu Changchang said that he will continue to pay attention to domestic consumption, modern services, high technology, oligopolistic manufacturing and other directions.
In her view, many industries are growing rapidly, and the trend of increasing penetration rate still exists, and even accelerates further under the catalyst of inflation. In addition, the gradual growth of the new energy industry has led to the continuous strengthening of the driving force for other industries, and many enterprises have emerged new growth points.
New energy is also an area where she will maintain a relatively high allocation level, and better cost performance is one of her concerns in choosing individual stocks. Liu Changchang believes that the huge changes from energy generation to use brought about by the development of new energy will continue to become the main line of economic growth in the future. At the same time, many new growth opportunities are still being born in the manufacturing industry.
Zhao Bei, Wang Pei and others investigated Bide Medicine
According to the latest investor relations activity record sheet disclosed by Biode, 35 fund companies participated in the company's survey from October 12 to November 11, including well-known fund managers such as Zhao Bei of ICBC Credit Suisse Fund and Wang Pei of China Europe Fund.
In this round of research, Bidder introduced the company's development strategy, customer structure, self-developed products, overseas market expansion dynamics and other aspects. Bede believes that on the one hand, the company adopts a strategy of "horizontal development" based on the needs of customers, and its core competitiveness is "how fast is better to save". Among them, regarding "many", as of September 30, 2022, the number of spot varieties of the company's molecular blocks ranked first among domestic companies in the same industry; Regarding "Kuai", the company has built 8 regional centers in various pharmaceutical R&D highlands at home and abroad, which improves the distribution efficiency of molecular building block products, thereby improving the R&D process of customers.
On the other hand, on the basis of two major conditions, such as strong competitive advantage and large market demand for product lines, the company will adopt the development strategy of "in-depth breakthrough" in some product lines. At present, the company is focusing on the development of boron-containing molecular building blocks and fluorine-containing molecular building blocks.
As of the end of the third quarter of this year, ICBC Credit Suisse Fund was one of the institutional investors in the stock, but the main holdings of the stock were ETF products; CEIBS Fund is not among the institutional investors in the stock.
However, since the beginning of this month, both Guolian Securities and Kaiyuan Securities have given the company a "buy" rating. Kaiyuan Securities mentioned that with the increase in demand for molecular blocks above the kilogram level, it is expected that the company's revenue scale will be further expanded; At the same time, the company will further increase the proportion of self-research of products, which is expected to drive profitability and a clear growth path.
Guolian Securities said that molecular building blocks are small molecule compounds used to design and construct pharmaceutical active substances, which belong to the underlying structural compounds, and the use of molecular building blocks in the drug research and development stage can reduce subsequent synthesis steps, reduce costs and increase efficiency. The molecular block industry is highly prosperous, and the market share of domestic enterprises is expected to continue to increase, and the company is one of the earliest domestic pharmaceutical molecular block brands.
Wind data shows that as of November 17, fund companies have participated in the research activities of 340 listed companies since the beginning of this month. Among them, the listed company with the most participation in the survey by fund companies is Yiheda, and 132 fund companies have appeared in the company's research records. In the latest round of research, Harvest Fund, Xingquan Fund, Bosera Fund and other leading fund companies participated, and Gao Yi Asset also appeared in the list of research institutions.
More than 60 fund companies participated in the research activities of 3 listed companies, including Huacan Optoelectronics, BOE A and Hengdian Dongci; In addition, more than 50 fund companies have participated in the research of listed companies such as Pony Test, Richen Shares, MyHome Medical, and China Mineral Resources. On the whole, the survey of individual stocks in the electronic devices, semiconductors, healthcare equipment and other sectors has been favored by many fund companies.
According to the respective surveys of fund companies, Wells Fargo Fund participated in the survey as many as 40 times this month, which is the fund company with the largest number of research times, involving 34 individual stocks under investigation; This was followed by Harvest Fund and Bosera Fund, which participated in the survey 39 times and 34 times respectively this month. In addition, Penghua Fund and Huaxia Fund have participated in the survey of listed companies more than 30 times.
This article originated from CaiLian News Agency reporter Zhou Xiaoya